novaGo Promobility therapeutics

new challenge

NovaGo‘s antibody program targets cerebral stroke and spinal cord injury.

new perspective

Preclinical research has demonstrated that blockade of the growth inhibitor Nogo-A
is highly effective.

Preclinical research has demonstrated
that blockade of the growth inhibitor Nogo-A
is highly effective.

new stimulus

Clinically, any improvement of nerve fiber regeneration and neural circuit repair will have a strong impact on patients‘ outcome.

Clinically, any improvement of nerve fiber
regeneration and neural circuit repair will have
a strong impact on patients‘ outcome.

new challenge

NovaGo‘s antibody program targets cerebral stroke and spinal cord injury.

new perspective

Preclinical research has demonstrated that blockade of the growth inhibitor Nogo-A
is highly effective.

Preclinical research has demonstrated
that blockade of the growth inhibitor Nogo-A
is highly effective.

new stimulus

Clinically, any improvement of nerve fiber regeneration and neural circuit repair will have a strong impact on patients‘ outcome.

Clinically, any improvement of nerve fiber
regeneration and neural circuit repair will have
a strong impact on patients‘ outcome.

Who we are

NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration.

Stroke

Stroke is the leading cause of adult disability in the developed world and affects approximately 33 million patients worldwide, with an estimated 17 million people suffering a first stroke each year.

Spinal cord injury

Spinal cord injury caused by trauma affects up to 500,000 people each year worldwide. It often results in the disruption of nerve fibers in the spinal cord, causing both paralysis and loss of sensation.